Novel compound F15845 shows promise for angina
Overturning a century of prevailing thought, scientists are finding that neurons in the adult brain can remodel their connections. In work reported in the Nov. 24 online edition of the Proceedings of the National Academy of Sciences (PNAS) , Elly Nedivi, associate professor of neurobiology at the Picower Institute for Learning and Memory, and colleagues
Full Post: Neurons in adult brain can remodel their connections
A compound designed to prevent chest pains in heart patients has shown promising results in animal studies, say scientists.
In the second issue of the British Journal of Pharmacology to be published by Wiley-Blackwell, researchers from the Centre de Recherche Pierre Fabre in France, show that the novel compound F15845 has anti-angina activity and can protect heart cells from damage without the unwanted side effects often experienced with other drugs.
Because F15845 does not interfere with heart function, as some conventional drugs such as beta blockers do, it could be given as part of a combination therapy. “It’s completely different from other anti-angina drugs which directly interact with the function of the heart. So the idea is to do a co-administration with conventional heart drugs such as beta blockers,” says lead author of the study, Bruno Le Grand from the Centre de Recherche Pierre Fabre in Castres, France.
The drug works by blocking excess influxes of sodium into heart cells through ‘gate’ proteins called sodium channels. High levels of sodium in heart cells are associated with low oxygen levels, which cause angina and can in turn lead to the build up of toxic concentrations of calcium that are lethal to cells. A number of drugs that target sodium channels can block the influx, but they act universally on heart cells and can sometimes cause further heart irregularities.
F15845 specifically targets the sodium channels that are thought to cause the most damage, those responsible for what is known as the persistent sodium current, which causes a permanent excess sodium influx.
The study confirmed the drug’s anti-angina activity in laboratory animals. The researchers say the drug is absorbed well when given orally and represents a novel therapeutic opportunity for treating angina and possibly other cardiac pathologies.
“We know that in animals, we have acceptable bioavailability, but with the data that we have in human volunteers following phase I clinical trials we are very confident that it is above 70 per cent,” says Le Grand.
Long-term gene therapy resulted in improved cardiac function and reversed deterioration of the heart in rats with heart failure, according to a recent study conducted by researchers at Thomas Jefferson University’s Center for Translational Medicine. The study was published online in Circulation . The rats were treated with a gene that generates a peptide called
Full Post: Long-term gene therapy used to reverse heart damage in heart failure
Up until today scientists assumed that the adult heart is unable to regenerate. Now, researchers and cardiologists from the Max Delbr?nter for Molecular Medicine (MDC) Berlin-Buch and the Charité - Universit?medizin Berlin (Germany) have been able to show that this dogma no longer holds true. Dr. Laura Zelarayán and Assistant Professor Dr. Martin W. Bergmann
Full Post: Heart regenerates after infarction
Studies at the University of Pennsylvania School of Medicine on brain electrical signaling offer a fresh perspective on vertebrate evolution, provide additional evidence supporting Darwinian views of evolution, and may also lead to more effective treatment of epileptic seizures in infants. Researchers discovered how evolutionary changes produced a series of improvements in molecules generating electrical
Full Post: More scientific evidence supporting Darwinian views of evolution
A drug commonly used to treat epilepsy could help clear the plaques in the brain associated with Alzheimer’s disease, according to researchers at the University of Leeds. The plaques are known to lead to the progressive death of nerve cells in the brain linked to many forms of dementia. Sodium valproate - which is marketed
Full Post: Anti-seizure drug Epilim shows promise for Alzheimer’s
While the treatment of heart failure has improved over the past two decades, a new study reported in the European Journal of Heart Failure finds that “the use of evidence-based treatments appears to be imbalanced according to the gender of the patient”. In particular, the study found that female patients were less frequently treated
Full Post: The drug treatment of heart failure is influenced by the gender of the patient and of the physician